Concourse Financial Group Securities’s Stoke Therapeutics STOK Stock Holding History

Concourse Financial Group Securities’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-200	Closed	-$4K	–	2425
2021 Q4	$5K	Hold	200	–	–	﹤0.01%	2059
2021 Q3	$5K	Hold	200	–	–	﹤0.01%	2086
2021 Q2	$7K	Hold	200	–	–	﹤0.01%	1984
2021 Q1	$8K	Hold	200	–	–	﹤0.01%	1839
2020 Q4	$12K	Hold	200	–	–	﹤0.01%	1637
2020 Q3	$7K	Buy	+200	New	+$5.71K	﹤0.01%	1700

Other funds holding STOK

Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Concourse Financial Group Securities's STOK Position: Q1 2022 in Review

Concourse Financial Group Securities sold out of Stoke Therapeutics (STOK) in Q1 2022, closing a stake of 200 shares — an estimated $4K sold.

Concourse Financial Group Securities first reported a position in STOK in Q3 2020 and held it in 6 quarters. The position peaked at $12K in Q4 2020. 99 funds tracked by Wall St. Rank hold STOK as of Q1 2022.

Concourse Financial Group Securities reported no remaining Stoke Therapeutics position as of Q1 2022 after selling out during the quarter.
Concourse Financial Group Securities sold 200 Stoke Therapeutics shares in Q1 2022, an estimated $4K.
Concourse Financial Group Securities first reported a position in Stoke Therapeutics in Q3 2020 and held it in 6 quarters.
Concourse Financial Group Securities's Stoke Therapeutics position peaked at $12K in Q4 2020.
99 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2022.

Based on Concourse Financial Group Securities's 13F filing for Q1 2022, filed 9 May 2022.